Kevin T. Conroy

October 16, 2026

Abbott Labs launches Ensure Max Protein as earnings preview approaches. Abbott Laboratories introduced a new high‑protein nutritional drink, Ensure Max Protein, expanding its consumer health lineup. At the same time, investors are looking ahead to the company's third‑quarter earnings, with analysts focusing on revenue and earnings per share estimates. TD Cowen reaffirmed its positive view of Abbott, keeping a $135 price target, which aligns with the analyst consensus range. The stock is currently near a long‑standing support level around $99.90.

October 4, 2026

Align Technology Sets Q3 2026 Earnings Date for October 28. Align Technology has scheduled its third-quarter 2026 earnings release for October 28, 2026. This announcement comes as the stock trades near its 52-week low, prompting market discussions about whether the current valuation is reasonable after a significant decline. Analysts continue to watch the company's position in the dental equipment sector, with average price targets remaining above current levels.

October 11, 2026

Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.